Fibroblast cell surface receptors

Fibroblast cell surface receptors encompass a diverse and heterogeneous group of membrane-bound proteins expressed by fibroblasts, the primary cells responsible for synthesizing the extracellular matrix (ECM) and maintaining connective tissue integrity. This category includes several critical receptor families, most notably receptor tyrosine kinases such as Fibroblast Growth Factor Receptors (FGFRs) and Platelet-Derived Growth Factor Receptors (PDGFRs), as well as Transforming Growth Factor-beta (TGF-beta) receptors and various integrins [1][3]. These receptors mediate essential cellular responses to growth factors and cytokines, regulating fibroblast proliferation, migration, and the production of structural proteins like collagen [3]. In pathological conditions such as idiopathic pulmonary fibrosis and systemic sclerosis, overactivation of these receptors leads to excessive ECM deposition and organ dysfunction [1]. Furthermore, in the tumor microenvironment, cancer-associated fibroblasts (CAFs) express specific surface markers like Fibroblast Activation Protein (FAP), which promote tumor progression and immunosuppression [2][3]. Therapeutic targeting of these receptors is a major focus in treating fibrotic diseases and cancer; for example, the multi-kinase inhibitor nintedanib targets FGFR and PDGFR to slow the decline of lung function in fibrosis patients [1]. Other approaches include the development of FAP-targeted antibodies and CAR-T cells to specifically deplete CAFs within tumors [2]. However, because many of these receptors are also expressed on healthy cells (e.g., vascular or immune cells), therapeutic intervention can lead to safety concerns such as impaired wound healing, gastrointestinal toxicity, and cardiovascular issues [1]. References: [1] Wollin L, et al. (2015). Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal. [2] Lindner T, et al. (2018). Development of Quinoline-Based Guanidine-Free FAP Inhibitors. Journal of Medicinal Chemistry. [3] Kalluri R. (2016). The biology and function of fibroblasts in cancer. Nature Reviews Cancer.

Other names

Fibroblast surface markersFibroblast membrane proteinsFibroblast-associated surface receptors

Inhibition of receptor tyrosine kinase signaling (e.g., FGFR, PDGFR) and modulation of TGF-beta pathways to suppress fibroblast activation, myofibroblast differentiation, and excessive extracellular matrix deposition.